Novartis next generation CAR-T cell therapy CTL119 combined with ibrutinib shows high rate of responses in CLL patients
Basel, May 30, 2017 – Novartis announced findings from a pilot examine (NCT02640209) of CTL119 in combination with ibrutinib* in patients with relapsed/refractory chronic lymphocytic leukemia (CLL) who had been taking ibrutinib for at least six months and who were not in accomplish remission. All investigate patients had to have failed at least one prior regimen before ibrutinib or carried high-risk cytogenetics or mutations. The results, which will be introduced at the upcoming fifty three rd Annual Meeting of the American Society of Clinical Oncology (ASCO; abstract #7509; Monday, June Five, 1:15 PM CDT), that eight of nine evaluable patients had no signs of CLL in their bone marrow at three months. One of those patients had a partial response [1].
“The data from this pilot probe support the potential for CTL119, when combined with the kinase inhibitor ibrutinib, to induce clinically-significant responses in high-risk CLL patients who were unlikely to achieve a finish remission on ibrutinib alone,” said James Bradner, president of the Novartis Institutes for BioMedical Research. “CTL119 represents one of our latest advances in CAR-T cell therapy research and our broader commitment to pioneering breakthrough immuno-oncology treatments.”
The findings will be introduced by Saar Gill, MD, PhD, an assistant professor of Hematology-Oncology in the Perelman School of Medicine and the Abramson Cancer Center of the University of Pennsylvania.
CTL119 is a humanized CD19-directed chimeric antigen receptor T cell (CAR-T) cell therapy, which is different from typical puny molecule or biologic therapies because it is manufactured for each individual patient using their own cells. During the treatment process, T cells are drawn from a patient’s blood and reprogrammed in the laboratory to create T cells that are genetically coded to hunt the patient’s cancer cells and other B-cells voicing a particular antigen.
Results from the pilot examine also demonstrated that eight of nine patients had no signs of CLL in their bone marrow at three months as tested by flow cytometry and/or analysis for minimal residual disease (MRD)[1]. MRD, which measures the presence of residual abnormalities in the blood and bone marrow at the molecular level following treatment, is significant because it can be an indicator of potential relapse[Two].
CT scans were performed to measure the inclusion of CLL in the spleens and lymph knots of investigate patients. A number of patients demonstrated improvements in the cargo of disease in their spleens and lymph knots at three months, tho’ radiologic responses are less clear cut and they require longer follow-up[1].
In the probe, ten patients experienced cytokine release syndrome (CRS), two of which were grade Three. However, no patients required treatment with tocilizumab** and all patients recovered from CRS. One patient developed tumor lysis syndrome and two patients had febrile neutropenia [1].
CLL is one of the most common types of adult leukemia, which typically progresses leisurely over time[Trio]. The majority of patients will relapse after initial therapy[Four], and newer targeted therapies must be taken continuously for an indefinite period of time[Five]. These are clear indications of the high unmet medical need for fresh therapies for CLL.
About the Novartis CAR-T Program
During the collaboration inbetween Novartis and the University of Pennsylvania, researchers generated the humanized anti-CD19 CAR, CTL119. CTL119 is in initial clinical development for numerous B-cell malignancies. Because CTL119 and CTL019 are investigational therapies, the safety and efficacy profile has not yet been established. Access to investigational therapies is available only through cautiously managed and monitored clinical trials. These trials are designed to better understand the potential benefits and risks of the therapy. Because of the uncertainty of clinical trials, there is no assure that CTL119 or CTL019 will become commercially available.
* Ibrutinib is marketed as IMBRUVICA®, a registered trademark possessed by Pharmacyclics LLC.
** Tocilizumab is marketed as ACTEMRA®, which is a registered trademark of Chugai Seiyaku Kabushiki Kaisha Corp., a member of the Roche Group.
Novartis Next Generation CAR-T Cell Therapy CTL119 Combined with Ibrutinib Shows High Rate of Responses in CLL Patients
Novartis Next Generation CAR-T Cell Therapy CTL119 Combined with Ibrutinib Shows High Rate of Responses in CLL Patients
Basel, May 30, two thousand seventeen – Novartis announced findings from a pilot probe (NCT02640209) of CTL119 in combination with ibrutinib* in patients with relapsed/refractory chronic lymphocytic leukemia (CLL) who had been taking ibrutinib for at least six months and who were not in finish remission. All probe patients had to have failed at least one prior regimen before ibrutinib or carried high-risk cytogenetics or mutations. The results, which will be introduced at the upcoming 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO; abstract #7509; Monday, June Five, 1:15 PM CDT), that eight of nine evaluable patients had no signs of CLL in their bone marrow at three months. One of those patients had a partial response [1].
“The data from this pilot explore support the potential for CTL119, when combined with the kinase inhibitor ibrutinib, to induce clinically-significant responses in high-risk CLL patients who were unlikely to achieve a accomplish remission on ibrutinib alone,” said James Bradner, president of the Novartis Institutes for BioMedical Research. “CTL119 represents one of our latest advances in CAR-T cell therapy research and our broader commitment to pioneering breakthrough immuno-oncology treatments.”
The findings will be introduced by Saar Gill, MD, PhD, an assistant professor of Hematology-Oncology in the Perelman School of Medicine and the Abramson Cancer Center of the University of Pennsylvania.
CTL119 is a humanized CD19-directed chimeric antigen receptor T cell (CAR-T) cell therapy, which is different from typical puny molecule or biologic therapies because it is manufactured for each individual patient using their own cells. During the treatment process, T cells are drawn from a patient’s blood and reprogrammed in the laboratory to create T cells that are genetically coded to hunt the patient’s cancer cells and other B-cells voicing a particular antigen.
Results from the pilot explore also showcased that eight of nine patients had no signs of CLL in their bone marrow at three months as tested by flow cytometry and/or analysis for minimal residual disease (MRD)[1]. MRD, which measures the presence of residual abnormalities in the blood and bone marrow at the molecular level following treatment, is significant because it can be an indicator of potential relapse[Two].
CT scans were performed to measure the inclusion of CLL in the spleens and lymph knots of investigate patients. A number of patients displayed improvements in the cargo of disease in their spleens and lymph knots at three months, tho’ radiologic responses are less clear cut and they require longer follow-up[1].
In the explore, ten patients experienced cytokine release syndrome (CRS), two of which were grade Three. However, no patients required treatment with tocilizumab** and all patients recovered from CRS. One patient developed tumor lysis syndrome and two patients had febrile neutropenia [1].
CLL is one of the most common types of adult leukemia, which typically progresses leisurely over time[Trio]. The majority of patients will relapse after initial therapy[Four], and newer targeted therapies must be taken continuously for an indefinite period of time[Five]. These are clear indications of the high unmet medical need for fresh therapies for CLL.
About the Novartis CAR-T Program
In 2012, Novartis and the University of Pennsylvania entered into a global collaboration to further research, develop and then commercialize CAR-T cell therapies for the investigational treatment of cancers. In March 2017, Novartis announced that the US Food and Drug Administration (FDA) accepted the company’s Biologics License Application filing and granted priority review for CTL019 in the treatment of relapsed/refractory (r/r) pediatric and youthfull adult patients with B-cell acute lymphoblastic leukemia. In April 2017, FDA granted Breakthrough Therapy designation to CTL019 for relapsed/refractory diffuse large B-cell lymphoma.
During the collaboration inbetween Novartis and the University of Pennsylvania, researchers generated the humanized anti-CD19 CAR, CTL119. CTL119 is in initial clinical development for numerous B-cell malignancies. Because CTL119 and CTL019 are investigational therapies, the safety and efficacy profile has not yet been established. Access to investigational therapies is available only through cautiously managed and monitored clinical trials. These trials are designed to better understand the potential benefits and risks of the therapy. Because of the uncertainty of clinical trials, there is no ensure that CTL119 or CTL019 will become commercially available.
The foregoing release contains forward-looking statements that can be identified by words such as “next generation,” “being developed,” “committed,” “will,” “upcoming,” “potential,” “commitment,” “investigational,” “priority review,” “Breakthrough Therapy designation,” or similar terms, or by express or implied discussions regarding potential marketing approvals for CTL119 and CTL019, or regarding potential future revenues from CTL119 and CTL019. You should not place undue reliance on these statements. Such forward-looking statements are based on the current beliefs and expectations of management regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forward in the forward-looking statements. There can be no assure that CTL119 or CTL019 will be submitted or approved for sale in any market, or at any particular time. Neither can there be any assure that the collaboration with the University of Pennsylvania will achieve any or all of its intended goals and objectives or be successful, or at any particular time. Nor can there be any assure that CTL119 or CTL019 will receive regulatory approval or be commercially successful in the future. In particular, management’s expectations regarding CTL119, CTL019 and the collaboration with the University of Pennsylvania could be affected by, among other things, the achievement of, or failure to achieve, any or all of the intended goals and objectives of the collaboration with the University of Pennsylvania; the uncertainties inherent in research and development, including clinical trial results and extra analysis of existing clinical data; regulatory deeds or delays or government regulation generally; the company’s capability to obtain or maintain proprietary intellectual property protection; general economic and industry conditions; global trends toward health care cost containment, including ongoing pricing and reimbursement pressures; safety, quality or manufacturing issues, and other risks and factors referred to in Novartis AG’s current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of fresh information, future events or otherwise.
** Tocilizumab is marketed as ACTEMRA®, which is a registered trademark of Chugai Seiyaku Kabushiki Kaisha Corp., a member of the Roche Group.
About Novartis
Novartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, cost-saving generic and biosimilar pharmaceuticals and eye care. Novartis has leading positions globally in each of these areas. In 2016, the Group achieved net sales of USD 48.Five billion, while R&D via the Group amounted to approximately USD 9.0 billion. Novartis Group companies employ approximately 118,000 full-time-equivalent associates. Novartis products are sold in approximately one hundred fifty five countries around the world. For more information, please visit http://www.novartis.com.
Novartis is on Twitter. Sign up to go after @Novartis at http://twitter.com/novartis (link is outer) and @NovartisScience at http://twitter.com/novartisscience (link is outward) For Novartis multimedia content, please visit www.novartis.com/news/media-library For questions about the site or required registration, please contact [email protected]
[Two] Campana, Dario. Minimal Residual Disease in Acute Lymphoblastic Leukemia. Seminars in hematology 46.1 (2009): 100-106. PMC. Web. Twenty two May 2017.
[Trio] National Cancer Institute. Chronic Lymphocytic Leukemia Treatment (PDQ®)-Patient Version. Available at https://www.cancer.gov/types/leukemia/patient/cll-treatment-pdq (link is outer). Accessed May 2017.
[Four] Veliz M, Pinilla-Ibarz J. Treatment of relapsed or refractory chronic lymphocytic leukemia. Cancer Control. 2012; 1:37-53
[Five] National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Chronic Lymphocytic Leukemia/Petite Lymphocytic Leukemia. Version Two.2017. Twenty one February 2017.